PharmAust is pleased to announce the successful completion of its Share Purchase Plan, raising $7.8 million, significantly exceeding the initial target of $2 million. This, combined with the recent institutional Placement, brings total proceeds to $17.8 million, reducing future funding needs for the HEALEY ALS Platform Trial. Shareholders showed exceptional support, allowing all valid applications to be accepted, strengthening our commitment to advancing monepantel for ALS and other neurodegenerative conditions.<br/><br/>The funds raised will be used for the HEALEY ALS Platform Trial, GMP manufacturing, regulatory filings, and more. With recent positive results in the Phase 1 MEND study and inclusion in the HEALEY ALS Platform Trial, PharmAust is well-positioned for accelerated development and potential FDA approval by 2026.<br/><br/>We appreciate the ongoing support from our shareholders and invite any questions about this announcement or our strategic direction. Visit our Investor Hub for more information and to engage with our team.